|
|
The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathyKeywords: efficacy, end-stage liver disease, healthcare utilization, hepatic encephalopathy, rifaximin-α, safety Abstract: After 5？？years since the registration of rifaximin-α as a secondary prophylaxis for overt hepatic encephalopathy (HE) in the Netherlands, we aimed to evaluate the use of hospital resources and safety of rifaximin-α treatment in a real-world setting
|
